Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.53 |
| ▸ | MAOA | P21397 | 4/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366805 | 1.00 | MAOB (0.53) | MAOBMAOAABCG2ARGUSB | |
| SCHEMBL1366807 | 1.00 | MAOB (0.53) | MAOBMAOAABCG2ARGUSB | |
| SCHEMBL1369244 | 0.91 | ABCG2 (0.58) | MAOBMAOAABCG2MEN1NPC1 | |
| SCHEMBL1367939 | 0.91 | ABCG2 (0.58) | MAOBMAOAABCG2MEN1NPC1 | |
| SCHEMBL1367940 | 0.91 | ABCG2 (0.58) | MAOBMAOAABCG2MEN1NPC1 | |
| SCHEMBL1365826 | 0.90 | STAT3 (0.55) | MAOBMAOAABCG2ARGUSB | |
| SCHEMBL1365828 | 0.90 | STAT3 (0.55) | MAOBMAOAABCG2ARGUSB | |
| SCHEMBL1368977 | 0.90 | STAT3 (0.55) | MAOBMAOAABCG2ARGUSB | |
| SCHEMBL1369175 | 0.86 | PTPN5 (0.54) | MAOBABCG2MEN1NPC1MAPT | |
| SCHEMBL1369174 | 0.86 | PTPN5 (0.54) | MAOBABCG2MEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | claimed |
| US-8067461-B2 | 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | NQO2, NQO1, HCCS | MAOB 2929/4885MAOA 3570/4885ABCG2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.